Buscar
Mostrando ítems 21-30 de 80
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
(NATURE PUBLISHING GROUP, 2011)
Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-alpha family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in ...
Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia.
(2013-07-08)
Objective: To evaluate the hematological, cytogenetic, and molecular
responses in Colombian patients with CML chronic
myeloid leukemia (CML) treated with imatinib.
Methods: Two groups of patients, one with the novo ...
Monitoração molecular da Leucemia Mielóide Crônica na era do imatinibe
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2008)
Nos últimos dez anos, o tratamento da leucemia mielóide crônica (LMC) passou por uma grande mudança com a introdução da terapia alvo, onde o mesilato de imatinibe (MI) atua inibindo a atividade tirosina quinase do transcrito ...
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2011)
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia ...
Relationship between the type of BCR-ABL rearrangement and bone marrow histopathological features in chronic myeloid leukemia
(Scandinavian University PressOsloNoruega, 1997)
CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease
(Taylor & Francis, 2014-03)
Patients with chronic myeloid leukemia (CML) can develop disease resistance to tyrosine kinase inhibitor (TKI) therapy, which is mainly attributable to the presence of point mutations in the tyrosine kinase domain of ...
Monitoramento da resposta molecular aos inibidores de tirosino-quinase em pacientes com leucemia mieloide crônica
(Universidade Federal de Santa MariaBrasilCiências da SaúdeUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da Saúde, 2019-02-28)
Chronic Myeloid Leukemia (CML) is associated with the chromosome Philadelphia. This abnormal
chromosome forms the chimeric BCR-ABL1 gene, which is responsible for producing a protein with
tyrosine kinase activity. Tyrosine ...
Diseño y estandarización de una técnica para la amplificación isotérmica mediada por bucles (LAMP) para la detección del gen BCR-ABL1 en Leucemia Mieloide crónica (LMC)
(Ediciones Universidad Simón BolívarFacultad de Ciencias Básicas y Biomédicas, 2023)
La leucemia mieloide crónica (LMC) se define como un síndrome mieloproliferativo crónico de origen clonal, que se genera de una célula madre, como consecuencia de la producción descontrolada de una proteína cinasa única ...